๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations

โœ Scribed by Ira M. Longini Jr.; Karen Sagatelian; Wasima N. Rida; M. Elizabeth Halloran


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
171 KB
Volume
17
Category
Article
ISSN
0277-6715

No coin nor oath required. For personal study only.

โœฆ Synopsis


Vaccination can have important indirect effects on the spread of an infectious agent by reducing the level of infectiousness of vaccinees who become infected. To estimate the effect of vaccination on infectiousness, one typically requires data on the contacts between susceptible and infected vaccinated and unvaccinated people. As an alternative, we propose a trial design that involves multiple independent and interchangeable populations. By varying the fraction of susceptible people vaccinated across populations, we obtain an estimate of the reduction in infectiousness that depends only on incidence data from the vaccine and control groups of the multiple populations. One can also obtain from these data an estimate of the reduction of susceptibility to infection. We propose a vaccination strategy that is a trade-off between optimal estimation of vaccine efficacy for susceptibility and of vaccine efficacy for infectiousness. We show that the optimal choice depends on the anticipated efficacy of the vaccine as well as the basic reproduction number of the underlying infectious disease process. Smaller vaccination fractions appear desirable when vaccine efficacy is likely high and the basic reproduction number is not large. This strategy avoids the potential for too few infections to occur to estimate vaccine efficacy parameters reliably.


๐Ÿ“œ SIMILAR VOLUMES


Augmented HIV vaccine trial design for e
โœ Susmita Datta; M. Elizabeth Halloran; Ira M. Longini Jr. ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 222 KB ๐Ÿ‘ 1 views

It is important to design HIV vaccine trials to estimate the efficacy of a vaccine in reducing infectiousness in addition to the protective efficacy. Currently planned phase III HIV vaccine field trials in which at-risk individuals are randomized and followed over time do not permit estimation or te